|From: bdawgp (Rep: 343)||Date: 10/06/2015 20:45|
|Forum: DepoMed - Msg #293||Thread #673784810 (Rec: 0) |
|still trading around 18, anything under 20 is another gift from this bio selloff...less than 8 forward p/e and only 2x rev's estimates for 2017 per Zacks|
"Based on our long term financial model, revenue will reach $352 million in 2015 with non-GAAP earnings per share (EPS) of $1.00. We continue to expect that the NUCYNTA® / ER deal will be strongly accretive, and that Depomed will generate $400 million in sales from NUCYNTA franchise in 2017. Non-GAAP EPS will grow from $1.00 in 2015 to $2.30 in 2017 based on total revenue of $624 million. "
disclaimer: good luck, markets are systems to fool the masses
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.